Prominent publications by Jolanta Weglowska
BACKGROUND: Early clinical studies suggested that the anti-interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the treatment of psoriasis.
METHODS: In two phase 3 studies (AMAGINE-2 and AMAGINE-3), patients with moderate-to-severe psoriasis were randomly assigned to receive brodalumab (210 mg or 140 mg every 2 weeks), ustekinumab (45 mg for patients with a body weight ≤100 kg and 90 mg for patients >100 kg), or placebo. At week 12, patients receiving brodalumab were ...
|Also Ranks for: Brodalumab Patients | placebo week | phase 3 studies | ustekinumab psoriasis | monoclonal antibodies|
Jolanta Weglowska: Influence Statistics
|moderatetosevere psoriasis brodalumab||#64|
|monoclonal humanized candidiasis||#70|
Key People For Week Patients
Jolanta Weglowska:Expert Impact
Concepts for whichJolanta Weglowskahas direct influence:Week patients, Brodalumab patients, Patients brodalumab, Phase 3 studies, Placebo week, Brodalumab placebo, Plaque psoriasis, Placebo brodalumab.
Jolanta Weglowska:KOL impact
Concepts related to the work of other authors for whichfor which Jolanta Weglowska has influence:Plaque psoriasis, Psoriatic arthritis, Monoclonal antibodies, Brodalumab patients, Th17 cells, Biologic agents, Atopic dermatitis.
Is this your profile? Claim your profile Copy URL Embed Link to your profile